In July 2020, remimazolam besylate (manufacturer: Byfavo) was accepted with the FDA with the induction and maintenance of procedural sedation in adults undergoing methods lasting 30 minutes or considerably less. There’s some evidence that the α5 BZD receptor is largely involved with the amnesic effects of benzodiazepines (and also other a